Page last updated: 2024-08-22

platinum and Lymphopenia

platinum has been researched along with Lymphopenia in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Appleman, L; Belani, CP; Beumer, JH; Chen, A; Chew, H; Chu, E; Diergaarde, B; Ding, F; Duan, W; Garcia, AA; Giranda, V; Hurley, RM; Ivy, SP; Ji, J; Katz, T; Kaufmann, SH; Kiesel, BF; Lee, JJ; Lin, Y; Manzo, J; Morgan, RJ; Oesterreich, S; Pahuja, S; Parchment, RE; Puhalla, S; Shepherd, SP; Stoller, R; Swisher, EM; Tan, AR; Tawbi, H; Visscher, DW; Wahner Hendrickson, AE; Yu, J; Zhang, Y	1

Trials

1 trial(s) available for platinum and Lymphopenia

Article	Year
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Female; Humans; Lymphopenia; Nausea; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Seizures; Triple Negative Breast Neoplasms	2022

Article

Year

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.

Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:5

Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Female; Humans; Lymphopenia; Nausea; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Seizures; Triple Negative Breast Neoplasms

2022